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Abstract: Osteoporosis poses a signiﬁ  cant public health issue, causing signiﬁ  cant morbidity 
and mortality. Calcium and vitamin D utilization in the optimization of bone health is often 
overlooked by patients and health care providers. In addition, the optimal standard of care 
for osteoporosis should encompass adequate calcium and vitamin D intake. Dietary intake or 
supplementation with calcium and vitamin D will be reviewed, including recent recommendations 
for increased vitamin D intake. Compliance to calcium and vitamin D therapy is paramount for 
effective prevention of osteoporotic fractures. A recently released algorithm (FRAX) estimating 
absolute fracture risk allows the health care provider to decide when pharmacologic therapy 
is warranted in addition to calcium and vitamin D. When pharmacologic therapy is advised, 
continued use of calcium and vitamin D is recommended for optimal fracture risk reduction. 
A ‘bricks and mortar’ analogy is often helpful when counseling patients and this analogy will 
be explained. This manuscript reviews relevant data related to calcium and vitamin D use for 
patients at risk for fracture due to bone loss.
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Osteoporosis overview
The skeletal disease of bone thinning and compromised bone strength, osteoporosis, 
continues to be a major public health issue as the population ages. This disease is 
characterized by bone fragility and an increased susceptibility to fractures, especially 
of the spine and hip, although any bone can be affected. It is estimated that over 10 
million Americans over the age of 50 have osteoporosis. Risk for osteoporosis has been 
reported in people of all ethnic backgrounds. An additional 34 million have reduced 
bone mass, called osteopenia, which puts them at higher risk for fractures later in life 
(USDH 2004). The risk of fracture from osteoporosis increases with age. There are 
approximately 1.5 million osteoporotic fractures per year reported in women and men 
in the US, including over 300,000 hip fractures. As the population ages, this number 
will probably increase. The US Surgeon General estimates that one out of every two 
women over the age of 50 will have an osteoporosis-related fracture in their lifetime. 
In addition, 20% of those affected by osteoporosis are men with 6% of white males 
over the age of 50 suffering a hip fracture. It is estimated that the national direct care 
costs for osteoporotic fractures is US$12.2 to 17.9 billion per year in 2002 dollars, 
with costs rising. This cost is comparable to the Medicare expense for coronary heart 
disease ($11.6 billion) (Thom et al 2006).
Since bone loss occurs without symptoms, osteoporosis is often considered a ‘silent 
disease’. As deterioration of bone tissue mounts and disruption of bone architecture 
occurs, the bone becomes so weak that a relatively minor bump or fall causes a frac-
ture or vertebrae to collapse. The resulting fracture may lead to loss of mobility and 
independence, with 25% requiring long term care (NAMS 2006). Fractures caused 
by either osteoporosis or low bone mass can lead to chronic pain, disability, as well as Therapeutics and Clinical Risk Management 2008:4(4) 828
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psychological symptoms, including depression. A woman’s 
risk of hip fracture is equal to her combined risk of breast, 
uterine and ovarian cancer). Unfortunately, approximately 
24% of patients with hip fractures over the age of 50 will die 
in the year following the fracture (NOF 2008).
Fortunately, the importance of this debilitating bone 
disease is being recognized. President Bush has declared 
2002–2011 as the Decade of the Bone and Joint. Important 
advances have been made to understand the disease process 
and help create therapies to treat the condition. Bone health 
is optimized by creating an environment to achieve peak 
bone mass during adolescence, maintenance of healthy 
bone throughout life and prevention of bone loss with aging. 
Health care providers are vital to identify patients at risk for 
bone loss and diagnose bone thinning so that prevention and 
treatment strategies are effective.
The US Surgeon General has outlined a ‘pyramid 
approach’ to treating bone diseases. Prevention of falls with 
maintenance of bone health through adequate calcium, vita-
min D, and physical activity represent the base of the pyramid 
for all individuals, including those with bone disease. The 
second tier of this pyramid relates to identifying and treat-
ing secondary causes of osteoporosis. Lastly, the third tier 
revolves around pharmacotherapy (USDH 2004).
Calcium and vitamin D have long been recognized as 
important and required nutrients for bone health and mainte-
nance. The continuation of calcium and vitamin D in a patient 
with bone loss is critical for optimal care. Unfortunately, 90% 
of women may not be getting enough calcium and over 50% 
of women treated for bone loss have inadequate vitamin D 
levels (NDC 2004; Holick et al 2005). Currently, there are a 
number of pharmacologic treatments for osteoporosis which 
provide improvements in bone mass and reduction in fracture 
risk. These treatments have been studied where adequate 
calcium and vitamin D supplementation had been achieved. 
Therefore, their use is predicated on proper calcium and 
vitamin D therapy. The goal of this manuscript is to review 
data related to calcium and vitamin D in the management 
of osteoporosis.
Calcium 
Nutrition
Peak bone mass is usually achieved by age 30; therefore, 
physical activity and obtaining the recommended doses of 
calcium and vitamin D in adolescence and young adult-
hood will ensure peak bone mass development (Table 1) 
(IOM 1997). Calcium is an essential element in the human 
body and is necessary to many cell functions. Calcium is 
not only important to bone health, but it is also essential 
for neuromuscular activity, blood coagulation, and normal 
cardiac function. It is a vital component of bone architecture 
and is required for deposition of bone mineral throughout 
life. Although the body stores more than 99% of its calcium 
in the bones and teeth, it is also found in the extracellular 
ﬂ  uid (ECF) or plasma. It is the levels of plasma calcium that 
dictate calcium balance. If the plasma level decreases, bone 
resorption increases to restore plasma levels. Adequate intake 
of calcium is necessary to maintain this balance. Calcium is 
absorbed in the small intestines with the aid of vitamin D 
(Bringhurst et al 2005). Excretion of calcium is primarily 
through the kidneys, although there is minor fecal loss.
The best way to meet the daily dietary requirement is 
through the intake of high calcium containing foods. Dairy 
products are the best sources of calcium due to their high 
elemental calcium content, high absorptive rate, and relative 
low cost. Dietary sources of calcium include dairy products 
(milk, cheese, yogurt) and some green vegetables. Each daily 
dairy serving consumed contains approximately 300 mil-
ligrams. A serving size of dairy equals one cup (8 ounces) 
of milk, one cup of yogurt or one to 1.5 ounces of cheese. 
Therefore, each daily dairy serving multiplied by 300 mg 
would provide an estimated total elemental calcium consump-
tion (IOM 1997). Mineral waters enriched with calcium are 
another source of dietary calcium. A recent study showed that 
high-calcium mineral waters had absorbabilities equal to milk 
calcium or slightly better and may provide useful quantities 
of bio-available calcium (Heaney 2006).
The individuals who do not obtain enough calcium from 
foods should take a supplement to meet these guidelines. 
Evidence suggests that the average American does not meet 
the lower end of the recommended daily calcium intake. The 
average women over the age of 40 has a calcium intake of 
less than half the amount recommended for postmenopausal 
Table 1 Recommended dietary intake of calcium and vitamin D. 
Adapted with permission from Institute of Medicine, Food and 
Nutrition Board (1997)
Age (years) Calcium (mg/day) Vitamin D (IU/day)
4–8 800 200
9–13 1300 200
14–18 1300 200
19–30 1000 200
31–50 1000 200
51–70 1200 400
70 1200 600Therapeutics and Clinical Risk Management 2008:4(4) 829
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women. In one study, 82% of patients with osteoporosis were 
taking less than the recommended 1000 mg daily (Black et al 
1996). This highlights the need for calcium supplementation 
in all patient populations. In fact, patients with osteoporosis 
are more likely to have a history of inadequate dietary calcium 
intake (NIH 1994).
Supplements
In order to assure adequate calcium intake, a number 
of calcium supplements are readily available. The two 
most common and well-studied calcium supplements are cal-
cium carbonate and calcium citrate. Both supplements have 
been shown to be equally well absorbed when taken with food 
(Heaney et al 2001). In the past, it was assumed that gastric 
acid secretion and gastric acidity played a critical role in the 
intestinal absorption of calcium. A randomized crossover 
trial demonstrated that the proton pump inhibitor, omepra-
zole, markedly decreased fractional calcium absorption from 
calcium carbonate when ingested by elderly women after an 
overnight fast on an empty stomach (O’Connell et al 2005). In 
addition, a case control study reported that long-term proton 
pump inhibitor therapy, particularly at high doses, was associ-
ated with an increased risk of hip fracture (Yang et al 2006). 
Research appears to support that calcium absorption can be 
ensured by ingestion with food. Recker (1985) reported nor-
mal absorption of calcium carbonate supplements when taken 
with a meal, even in achlorhydric patients. A study to evaluate 
the role of gastric acid on calcium absorption reported that a 
large does of cimetidine, which reduced gastric acid secre-
tion, had no effect on calcium absorption from carbonate or 
citrate sources. In addition, calcium carbonate absorption 
was the same whether gastric contents were maintained at a 
pH of 7.4 or 3.0 (Bo-Linn et al 1984).
Calcium carbonate supplements have the highest percent-
age of elemental calcium among the calcium salts (Table 2). 
Calcium carbonate contains 40% elemental calcium com-
pared to 21% found in calcium citrate, 13% found in calcium 
lactate, and 9% found in calcium gluconate (Weisman 2005). 
From a patient perspective, this translates into fewer calcium 
carbonate tablets required to achieve optimal intake on a daily 
basis. Quality calcium products should come from a repu-
table manufacturer who can provide adequate absorbability 
and bioavailability data. Given equivalent bioavailability of 
carbonate and citrate supplements, the cost beneﬁ  t analysis 
favors the less expensive carbonate products. In fact, a 
leading calcium citrate product (Citracal) was reported to cost 
1.5–1.8 times a leading calcium carbonate (OsCal) product 
when comparing grams of elemental calcium (Heaney et al 
2001).
To ensure optimal absorption, patients should be coun-
seled to take their calcium supplements with meals in divided 
doses. Since the GI tract can only absorb 500 to 600 mg of 
calcium at one time, supplements should be spaced by at 
least four to ﬁ  ve hours to achieve the recommended intake 
(Heaney et al 1975).
Side effects from calcium supplements are few. Although 
GI side effects are often mentioned, the recently reported 
Women’s Health Initiative (WHI) did not reveal any differ-
ence between the calcium/vitamin D group and placebo group 
in the rate of adverse GI events, such as gas, bloating, or 
constipation (Jackson et al 2006). Clinically, it is worthwhile 
to recommend initiating a calcium/vitamin D supplement at a 
lower dose with gradual titration to the target intake amount 
over 1–2 months in patients that describe GI symptoms.
Drug interactions
Calcium supplements have the potential to interact with sev-
eral prescription and over the counter medications. Calcium 
supplements may decrease levels of the drug digoxin. The 
interaction between calcium and vitamin D supplements and 
digoxin may also increase the risk of hypercalcemia. Calcium 
supplements also interact with ﬂ  uoroquinolones, levothyrox-
ine, antibiotics in the tetracycline family, and phenytoin. In all 
of these cases, calcium supplements decrease the absorption 
of these drugs when the two are taken at the same time (Jellin 
et al 2000; Shannon et al 2000).
Thiazide, and diuretics similar to thiazide, can interact 
with calcium and vitamin D supplements to increase the 
chances of developing hypercalcemia and hypercalciuria 
(Jellin et al 2000). Aluminum and magnesium antacids can 
both increase urinary calcium excretion. Mineral oil and 
stimulant laxatives can both decrease dietary calcium absorp-
tion (Jellin et al 2000).
In general, bisphosphonate drugs are poorly absorbed 
from the GI tract and can bind calcium. Therefore, bisphos-
phonate drugs should be taken on an empty stomach with a 
Table 2 Percentage of elemental calcium in common calcium salts. 
Adapted with permission from Weisman (2005)
Calcium salt Elemental calcium (%)
Carbonate 40
Tricalcium phosphate 38
Citrate 21
Lactate 13
Gluconate 9Therapeutics and Clinical Risk Management 2008:4(4) 830
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30–60 minute post-dose fast. To ensure adequate absorption, 
it is prudent to avoid taking calcium supplements around the 
dose of oral bisphosphonates.
Often, the physician identifying and treating the patient 
for bone loss is not the same health care provider treating 
other acute and chronic medical conditions. Therefore, it is 
imperative to understand the pharmacology of the medica-
tions prescribed to patients and the potential interactions with 
calcium and vitamin D supplements.
Food interactions
Achieving optimal calcium intake requirements through 
diet alone can prove even more difﬁ  cult in certain popula-
tions, such as vegetarians, those who are lactose intolerant 
and those with calorie-restriced diets. In addition, there are 
several substances that can interfere with the body’s abil-
ity to use calcium, including oxalate, protein, phytate, and 
caffeine.
Foods with high amounts of oxalate and phytate reduce 
the absorption of calcium contained in those foods. Spinach, 
rhubarb and beet greens are examples of foods that are high 
in oxalate. While these foods can be an important part of a 
healthy diet, they are not good sources of calcium.
Legumes, such as pinto beans, navy beans, and peas, 
are high in phytate. Wheat bran is also high in phytate. 
Therefore, it is recommended to avoid taking calcium 
supplements with oxalate- or phytate-rich foods to ensure 
adequate absorption.
Kidney stones
Kidney stones are crystallized deposits of calcium and other 
minerals in the urinary tract. Calcium oxalate stones are the 
most common form of kidney stones in the US. High calcium 
intakes or high calcium absorption were previously thought to 
contribute to the development of kidney stones. Other factors 
such as high oxalate intake and reduced ﬂ  uid consumption 
appear to be more of a risk factor in the formation of kidney 
stones than calcium in most individuals.
A 17% increase in kidney stone formation was seen in 
the WHI study. However, this increase in kidney stone forma-
tion is contrary to a number of prior studies that showed no 
increased risk or a decreased risk of kidney stone formation; 
further study is warranted. Borghi and colleagues (2002) 
reported a 50% reduction in stone recurrence in men with a 
history of kidney stones who were assigned a calcium diet of 
1200 mg/day compared to a low calcium group. Data from the 
Nurses Health Study who were followed for 12 years revealed 
that women with greater than 1000 mg/day calcium had lower 
risks of kidney stones compared to women with daily intake 
of less than 500 mg/day (Curhan et al 1997).
Vitamin D
Nutrition
Vitamin D is an important nutrient in the maintenance of 
bone health. The primary functions of vitamin D are the 
regulation of intestinal calcium absorption and the stimula-
tion of bone resorption leading to the maintenance of serum 
calcium concentration (Reid et al 2003). Sources of vitamin 
D include sunlight, diet, and supplements. The majority of 
Americans do not achieve adequate vitamin D levels. In fact, 
it is estimated that 90% of adults between 51 and 70 years 
of age do not get enough vitamin D from their diet (Moore 
et al 2004).
Sunlight exposure, or ultraviolet B (UVB) radiation, is 
absorbed by the 7- dehydrocholesterol that resides in the 
skin to form previtamin D3. Previtamin D3, an unstable 
compound, is quickly converted to vitamin D3 via heat 
(MacLaughlin et al 1982). Vitamin D3 moves out into the 
extracellular space and is drawn into the capillaries by vita-
min D-binding protein (DBP) (Holick 2005a). Once in the 
capillaries, the vitamin D is transported to the liver where 
it undergoes hydroxylation to form 25-hydroxyvitamin 
D [25(OH)D]. 25-hydroxyvitamin D is again bound by 
DBP and taken to the kidney where it is transported and 
released into the renal tubule cell and hydroxylated to form 
1,25-dihydroxyvitamin D [1,25(OH)2D] (DeLuca 2004). 
This is the biologically active form of vitamin D, which is 
responsible for calcium homeostasis.
Dietary sources of vitamin D are absorbed into the 
lymphatic system via chylomicrons, where they enter the 
circulation and are bound by DBP (Bouillon 2001). From 
here, they are taken to the liver and kidneys, as explained 
above, for the formation of the active form of vitamin D 
[1,25(OH)2D].
Vitamin D deﬁ  ciency
In vitamin D deﬁ  ciency states, decreased calcium absorp-
tion occurs from the intestines, causing increased osteoclast 
production, which enhances the mobilization of calcium 
from the bone. During periods of decreased dietary intake, 
1,25(OH)2D interacts with receptors in osteoblasts, ulti-
mately leading to increased formation of osteoclasts (Holick 
2004a). The mature osteoclast then releases enzymes to 
breakdown bone matrix ultimately releasing calcium and 
other minerals into the circulation (Holick 2005b). If the 
serum free calcium level remains low, the parathyroid gland Therapeutics and Clinical Risk Management 2008:4(4) 831
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is stimulated (Holick 2005a). Release of parathyroid hormone 
(PTH) causes increased renal reabsorption of calcium and 
also stimulates osteoclast production, leading to increased 
serum levels of calcium. If vitamin D deﬁ  ciency is not cor-
rected, calcium continues to be pulled from the bone and 
rickets can occur in children, while osteomalacia and osteo-
porosis can occur in adults.
Vitamin D sources
Sunlight is the most common source of vitamin D. Serum 
25(OH)D levels are lower in individuals who use sunscreens 
and in those with pigmented skin. A practical and common 
recommendation for adequate vitamin D from sunlight is ﬁ  ve 
to 15 minutes of sun exposure from the hours of 10 AM to 
3 PM in the spring, summer, and autumn at least two times 
per week to the face, arms, hands, or back. This is usually 
enough for people with most skin types to maintain adequate 
vitamin D levels (Holick 2004b). After this exposure, sun-
screen could be applied to limit solar skin damage. Therefore, 
it is important to remember that while harmful UV rays from 
sunlight can increase skin cancer risks, blocking these UV 
rays can predispose individuals to vitamin D deﬁ  ciency.
If sufﬁ  cient sunlight is not obtained, dietary sources of 
vitamin D can be utilized. Dietary sources of vitamin D 
include fatty ﬁ  sh such as salmon, mackerel, and sardines 
which provide 300 to 600 units/3.5 ounces, egg yolks which 
provide 20 units/yolk, and cod liver oil which provides 400 
units/teaspoonful. The most common dietary source of vita-
min D is found in fortiﬁ  ed foods such as milk, orange juice, 
and some cereals which provide about 100 units per serving 
(Tangpricha et al 2003; Holick 2004a).
Due to the relative lack of vitamin D-containing foods, 
supplements of vitamin D are often necessary to achieve 
an adequate intake. The National Osteoporosis Foundation 
(NOF) recommends an intake of 800 to 1000 international 
units (IU) of vitamin D3 per day for adults over age 50 
(NOF 2008). The safe upper limit for vitamin D intake for 
the general adult population was set at 2,000 IU per day in 
1997 (SCSEDR 1997). Recent evidence indicates that higher 
intakes are safe and that some elderly patients will need 
at least this amount to maintain optimal 25(OH)D levels 
(NOF 2008).
Dietary sources of vitamin D can come from plants 
(ergocalciferol or vitamin D2) or animals (cholecalciferol 
or vitamin D3). Supplements can come from either source. 
A review of the medical and lay press appears to conclude 
that vitamin D2 is less effective than vitamin D3 in main-
taining vitamin D status. A recent placebo controlled study 
compared intakes of 1000 units of D2 and 1000 units of 
D3 for 11 weeks at the end of winter. Interestingly, 67% 
of participants were vitamin D deﬁ  cient at the start of the 
study. The authors concluded that 1000 units of vitamin 
D2 daily was as effective as 1000 units of vitamin D3 in 
maintaining serum 25-hydroxyvitamin D levels (Holick et al 
2008). Therefore, vitamin D2 and D3 supplements should be 
considered comparable and of equal potency.
Since higher intakes of vitamin D can reduce bone 
resorption and subsequent bone loss, it appears that the rec-
ommended intake of vitamin D is in need of revised require-
ments, especially in older individuals. In an extensive review 
of the vitamin D literature, Vieth (1999) states that the daily 
reference intake should be 800–1000 units per day based 
upon bone density measurements and fracture prevention in 
the elderly. A recent report found that levels of 25(OH)D less 
than 10 ng/ml was linked to a 78% increase risk of falling in 
men and women over the age of 65 (Snijder et al 2006).
Fifty-two percent of North American women receiving 
therapy to prevent or treat osteoporosis were found to be 
vitamin D deﬁ  cient after measuring serum 25(OH)D levels 
(Holick et al 2005). Furthermore, a survey of childbearing 
women in the US found 41% of African American women 
between 15 and 49 years of age to be vitamin D deﬁ  cient at 
the end of winter (Nesby-O’Dell et al 2002). Lastly, 4% of 
Caucasian women were found to be vitamin D deﬁ  cient at 
the end of summer.
Vitamin D serum levels can be measured to determine 
vitamin D stores. The value that is measured is 25(OH)D 
because this compound has the longest half life (two weeks) 
and it correlates with secondary hyperparathyroidism, rick-
ets, and osteomalacia (unmineralized bone) (Holick 2006). 
The normal range of vitamin D (25(OH)D ) is 10–55 ng/ml 
(25–137.5 nmol/L) (Weaver and Fleet 2004). The desired 
adult level of vitamin D (25(OH)D) is 30 ng/ml (75 nmol/L) 
or higher (NOF 2008).
Osteoporosis
Diagnosis
Recently, the NOF released its new Clinician’s Guide to Pre-
vention and Treatment of Osteoporosis (NOF 2008). These 
guidelines are described as a major breakthrough in the way 
health care providers evaluate and treat patients with low bone 
mass or osteoporosis and the risk of fractures. The guidelines 
allow speciﬁ  c recommendations to many races, including Cau-
casian postmenopausal women, as well as African-American, 
Asian, Latina, and other postmenopausal women. It also 
addresses men aged 50 and older for the ﬁ  rst time.Therapeutics and Clinical Risk Management 2008:4(4) 832
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The most common clinical tool to diagnose osteoporosis 
and predict fracture risk is a bone mineral density (BMD) 
test. A measurement of bone density is often considered when 
it will help guide decisions regarding treatment to prevent 
osteoporotic fractures. The NOF recommends testing all 
women age 65 and older and men age 70 and older, regardless 
of clinical risk factors. Other indications for BMD testing 
include: (NOF 2008)
•  Younger postmenopausal women and men aged 50–70 
about whom you have concern based on their clinical 
risk factor proﬁ  le.
•  Women in the menopausal transition if there if a speciﬁ  c 
risk factor associated with increased fracture risk such as 
low body weight, prior low-trauma fracture, or high risk 
medication.
•  Adults who have a fracture after age 50.
•  Adults with a condition (eg, rheumatoid arthritis) or tak-
ing a medication (eg, glucocorticoids, 5 mg/day for 
3 months) associated with low bone mass or bone loss.
•  Anyone being considered for pharmacologic therapy for 
osteoporosis.
•  Anyone being treated for osteoporosis, to monitor treat-
ment effect.
•  Anyone not receiving therapy in whom evidence of bone 
loss would lead to treatment.
•  Postmenopausal women discontinuing estrogen therapy 
should be considered for bone density testing.
The updated NOF guidelines include the use of a new 
algorithm on absolute fracture risk, called FRAX by the 
World Health Organization (WHO). The FRAX algorithm 
takes into account not only BMD at the hip but also nine 
speciﬁ  c clinical risk factors for osteoporosis and related 
fractures. This algorithm estimates the 10-year hip fracture 
probability and 10-year all major osteoporosis-related frac-
ture probability. Treatment is recommended for patients with 
hip or vertebral (clinical or morphometric) fractures, as well 
as those with BMD T-scores  −2.5 at the femoral neck, total 
hip, or spine by DXA, after appropriate evaluation.
Treatment guidelines help the clinician decide which 
patients with osteopenia warrant pharmacologic treatment. 
Treatment is recommended for postmenopausal women and 
in men age 50 and older with low bone mass (T-score −1 to 
−2.5, osteopenia) at the femoral neck, total hip, or spine and 
10-year hip fracture probability 3% or a 10-year all major 
osteoporosis-related fracture probability of 20% based on 
the US-adapted WHO absolute fracture risk model.
Menopause often leads to increases in bone loss with 
the most rapid rates of bone loss occurring during the 
ﬁ  rst ﬁ  ve years after menopause (Gallagher et al 1987). 
A drop in estrogen production after menopause results in 
increased bone resorption, and decreased calcium absorption 
(Gallagher et al 1980; Breslau 1994). Annual decreases in 
bone mass of 3%–5% per year are often seen during the 
years immediately following menopause, with decreases 
less than 1% per year seen after age 65 (Daniels 2001). Post-
menopausal hormone therapy can decrease the incidence of 
osteoporosis and reduce fracture risk. However, since many 
women have elected to discontinue or avoid hormone therapy 
after menopause, it is imperative for health care providers to 
actively identify those women at risk for bone thinning and 
fracture. Counseling is especially prudent regarding weight 
bearing exercise and calcium/vitamin D intake during the 
perimenopause transition.
Treatment considerations
Calcium studies
Calcium supplementation has shown effectiveness for pre-
venting osteoporotic fractures in postmenopausal women. 
A meta-analysis reviewed the literature from 1966 to 1997 
assessing the effectiveness of calcium supplementation for 
the prevention of osteoporotic fractures in postmenopausal 
women. Only studies with fracture outcomes were eligible. 
This analysis revealed relative risk reductions between 25% 
to 70% for osteoporotic fractures. Most trials reported an 
approximate 30% fracture risk reduction with an intake of 
approximately 1000 mg/day of elemental calcium (Cum-
mings and Nevitt 1997).
Over 18 months, a trial of elderly French women found 
that the number of hip fractures was reduced by 43% 
and nonvertebral fractures was reduced by 32% among 
women treated with calcium (1200 mg/day) and vitamin 
D (800 units/day) than among those who received placebo 
(Chapuy et al 1992).
Dawson-Hughes and colleagues (1990) reported that 
bone loss is reduced in healthy, older postmenopausal 
women by increasing calcium intake from 400 mg/day to 
800 mg/day. In addition, postmenopausal women (within 
three to six years of menopause) supplemented with 
1700 mg/day of calcium had reduced bone loss from the 
femoral neck and improved calcium balance in a study 
of 118 healthy white women (Aloia et al 1994). Another 
study revealed that dietary supplementation of calcium and 
vitamin D in men and women over 65 years of age could 
reduce bone loss in the femoral neck and spine while reduc-
ing the incidence of nonvertebral fractures over three years 
(Dawson-Hughes et al 1997).Therapeutics and Clinical Risk Management 2008:4(4) 833
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A meta-analysis of 15 trials with 1806 study participants 
found that calcium alone caused a positive mean percentage 
BMD change from baseline of 2.05% for total body bone 
density, 1.66% at the lumbar spine, 1.6% at the hip, and 
1.9% at the distal radius. The data also showed a trend toward 
reduction in vertebral fractures, with relative risk reduction 
of 0.79 (95% CI 0.54 to 1.09). However, the risk reduction 
for nonvertebral fractures was unclear (RR = 0.86 (95% 
CI 0.43 to 1.72) (Shea et al 2004).
The recent RECORD trial studied 5292 people over 
70 years of age to evaluate the effectiveness of calcium 
and/or vitamin D supplements for the secondary prevention 
of fractures. Follow-up was between 24 and 62 months. 
The groups studied did not reveal signiﬁ  cant reductions in 
future fractures. However, compliance with the supplements 
was a signiﬁ  cant problem with this study. At 24 months, 
only 54.5% of subjects were still taking the supplement 
(Grant et al 2005).
A more recent meta-analysis of 29 studies, with over 
63,000 individuals analyzed, looked at calcium and calcium 
in combination with vitamin D trials for use in prevention 
of fracture and bone loss was recently reported. The authors 
concluded that treatment was associated with a 12% risk 
reduction in fractures of all types. Trials with higher compli-
ance revealed signiﬁ  cant risk reduction compared to studies 
with lower compliance. In the 8 studies with greater than 
80% compliance, a 24% risk reduction for all fractures was 
identiﬁ  ed. The author’s conclusions were that calcium, or 
calcium in combination with vitamin D supplementation, 
was effective in the preventive treatment of osteoporosis in 
people aged 50 years or older. It appeared that the best effect 
was seen with minimum doses of 1200 mg of calcium and 
800 units of vitamin D daily (Tang et al 2007).
Supplementation with vitamin D in individuals with 
severe calcium deﬁ  ciency did not lead to bone sparing. 
However, calcium repletion in study subjects with marginal 
vitamin D levels resulted in bone sparing. Therefore, opti-
mal intake of vitamin D is inﬂ  uenced by calcium intake. 
Optimal bone health requires both a high dietary calcium 
intake and high vitamin D intake (Weaver and Fleet 2004). 
Counseling patients that many calcium supplements also 
contain vitamin D is one convenient mechanism by which 
adequate supplementation can be achieved.
A recent study from the WHI reported results regard-
ing calcium and vitamin D supplementation and the risk of 
fractures. This study randomly assigned over 36,000 healthy 
postmenopausal women to receive daily doses of 1000 mg 
calcium carbonate and 400 units of vitamin D or placebo, 
with a seven-year follow up with respect to fractures and 
BMD. The conclusions drawn from the study revealed a 
small but signiﬁ  cant improvement in hip bone density, but 
no signiﬁ  cant reduction in hip fracture. This trial was well 
conducted but left many questions unanswered. Pertinent 
ﬁ  ndings within this study were that women who were adher-
ent to their study regimen (those who took over 80% of their 
study calcium/vitamin D) had a signiﬁ  cant 29% reduction in 
hip fracture. Women aged 60 and over (those at highest risk 
of fracture) had a signiﬁ  cant 21% reduction in hip fracture 
risk.
Sixty-four percent of women in the placebo group had 
a daily calcium intake from diet and supplements of at least 
800 mg and 42% had a daily vitamin D intake of at least 400 
units. In addition, the study participants had average daily 
calcium intakes of 1150 mg before the study began, which 
is nearly double the national average. Therefore, this intake 
may certainly reduce the chances of detecting a beneﬁ  t of 
additional calcium and vitamin D therapy in this study 
(Jackson et al 2006).
The data from these studies indicate a vital role for 
calcium and vitamin D related to optimal bone health. It is 
imperative that calcium and vitamin D counseling be con-
ducted throughout life. Ensuring peak bone development 
via adequate nutritional intake during adolescence along 
with continued repeated discussions throughout a person’s 
life can signiﬁ  cantly limit morbidity and mortality from 
osteoporosis. Poor compliance is a major obstacle in many 
medical regimens. Based on evidence presented, calcium and 
vitamin D supplementation compliance is vital to ensuring 
optimal risk reduction and fracture prevention.
Vitamin D studies
Vitamin D has been extensively studied regarding its impact 
on fracture risk reduction. In fact, vitamin D deﬁ  ciency has 
been associated with greater incidence of hip fracture in many 
populations, including postmenopausal women (Chapuy et al 
1992; Dawson-Hughes et al 1995). In a detailed review by 
LeBoff and colleagues (1999) of women with osteoporosis 
who were hospitalized due to hip fractures, 50% were found 
to have signs of vitamin D deﬁ  ciency.
Reasons for an increased risk of fracture associated 
with vitamin D deﬁ  ciency are numerous. Inability to absorb 
adequate amounts of calcium for optimal bone health, as well 
as an increased susceptibility of falling, impaired muscle 
strength, and increased rates of bone loss can increase the risk 
of fracture (Lips 2001). It has been reported that lower levels 
of vitamin D are independently associated with an increased Therapeutics and Clinical Risk Management 2008:4(4) 834
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risk of falling in the elderly. In fact, supplementation with 
vitamin D has been shown to improve musculoskeletal func-
tion and reduce the risk of falling in elderly women (Bischoff 
et al 2003). Human muscle contains vitamin D receptors 
that may lead to increasing muscle strength and improving 
stability (Snijder et al 2006). The combination of 700 units/
day of vitamin D and 500 mg of calcium (obtained through 
supplementation in addition to diet) was shown to reduce falls 
by as much as 65% over three years in less active women 
over the age of 65 (Bischoff-Ferrari et al 2006).
It appears that vitamin D supplementation may prove 
more beneﬁ  cial in reducing falls and increasing bone density 
in elderly women who have suffered a hip fracture when given 
with calcium (Harwood et al 2004). The Decalyos II study 
examined the effect of calcium and vitamin D supplementa-
tion over two years in a group of elderly women who were able 
to walk indoors with a cane or walker. Results suggested that 
such supplementation could reduce the risk of hip fractures 
in this population (Chapuy et al 2002).
All vitamin D trials from 1966 to 1999 for postmenopausal 
osteoporosis were evaluated in a meta-analysis to review the 
effect of vitamin D on bone density and fractures. Twenty-ﬁ  ve 
trials that randomized women to vitamin D with or without 
calcium and measured bone density or fracture for at least 
one year were chosen. The results revealed a 37% reduction 
in vertebral fractures (Papadimitropoulos et al 2002).
A Cochrane Database review reported that vitamin D 
alone showed no statistically signiﬁ  cant effect on hip frac-
ture, vertebral fracture, or any new fracture. Vitamin D with 
calcium marginally reduced hip fractures and nonvertebral 
fractures, but there was no evidence of effect of vitamin 
D with calcium on vertebral fractures. Compliance to the 
supplements was not reported. The effect appeared to be 
restricted to those living in institutional care. There was no 
evidence that vitamin D increased gastrointestinal symp-
toms or renal disease. The conclusion was that frail older 
people conﬁ  ned to institutions may sustain fewer hip and 
other nonvertebral fractures if given vitamin D with calcium 
supplements. Further investigation regarding dose, frequency, 
and route of administration of vitamin D in older people was 
recommended (Avenell et al 2005).
Another meta-analysis of randomized, controlled fracture 
prevention trials with vitamin D reported that oral vitamin D 
supplementation between 700 to 800 units per day appeared 
to reduce the risk of hip and any nonvertebral fractures in 
ambulatory or institutionalized elderly persons. An oral 
vitamin D dose of 400 IU/d was not sufﬁ  cient for fracture 
prevention. A vitamin D dose of 700 to 800 units per day 
reduced the relative risk of hip fracture by 26% and any 
nonvertebral fracture by 23% (Bischoff-Ferrari et al 2005). 
Subsequently, an enhanced meta-analysis was done to deﬁ  ne 
the need for additional calcium supplementation in individu-
als receiving vitamin D for the prevention of hip fractures. 
Findings suggested that oral vitamin D appears to reduce the 
risk of hip fractures only when calcium supplementation is 
added (Boonen et al 2007).
Pharmacological treatment
Currently, there are a number of prescription therapeutic 
options for the prevention and treatment of osteoporosis. The 
antiresorptive medications are the largest group and include 
bisphosphonates (Actonel, Boniva, Fosamax, Reclast), selec-
tive estrogen receptor modulators (Evista), hormone therapy 
and calcitonin (Miacalcin). Teriparatide is a parathyroid hor-
mone derivative that acts as an anabolic agent on bone and is 
indicated for post-menopausal women with osteoporosis who 
are at high risk of fracture (Eli Lilly 2008). A review of studies 
that led to the FDA approval of prescription medications used 
for the treatment of osteoporosis found that 80% of studies 
had been performed under conditions where a certain mini-
mum calcium and vitamin D intake was ensured (Sunyecz and 
Weisman 2005). Therefore, one cannot conclude that these 
prescription medications would be as effective in calcium 
and vitamin D deﬁ  cient patients. Unfortunately, calcium use 
during osteoporosis therapy is often under-utilized by patients 
and not appropriately counseled by physicians. In 1994, 
43% of osteoporosis visits had some form of counseling for 
calcium. By 2000, this proportion had declined to 29% and 
fell to 23% by 2004 (Stafford et al 2005).
An effective tool that can be used to help patients under-
stand the importance of calcium and vitamin D when using 
prescription medications for bone loss is the ‘brick and mor-
tar’ analogy. In the analogy, reference is made to building a 
strong structural foundation. The antiresorptive medication 
serves as the ‘bricks’, while adequate calcium and vitamin 
D serve as the ‘mortar’. Without both ‘brick’ and ‘mortar’, 
the structure (healthy bone) could not be achieved.
Oral bisphosphonate medications must be taken on an 
empty stomach. Package inserts for oral bisphosphonate 
caution that calcium supplements may interfere with bisphos-
phonate absorption and should be taken at a different time 
of day. Calcium citrate products can be taken on an empty 
stomach or with food, while calcium carbonate products 
should be taken with meals. Therefore, patients (especially 
calcium citrate users) need to be counseled to avoid taking 
their calcium supplements with bisphosphonates.Therapeutics and Clinical Risk Management 2008:4(4) 835
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It is imperative for the health care provider to be aware that 
adequate calcium and vitamin D stores must be present to allow 
pharmacologic treatments for osteoporosis to be effective.
Summary
Bone loss and osteoporosis with the resultant increase in 
fracture risk should be major concerns for patients and health 
care providers. As the population ages, the long term effects 
of osteoporosis including pain, loss of independence and 
institutionalized care will become more prevalent. Efforts to 
prevent bone loss and osteoporosis should start with proper 
education about a healthy lifestyle, including optimal calcium 
and vitamin D and exercise in adolescence. This education 
should continue throughout life, with emphasis during times 
of increased bone loss such as the menopause transition.
This paper reviews the cornerstone of bone health; calcium 
and vitamin D. Although dietary sources of both nutrients are 
available, most people do not receive adequate amounts for 
proper bone health. In addition, the heightened awareness of 
damaging effects of sunlight has limited vitamin D synthesis 
from the skin. Fortunately, supplements are available that can 
supply the body with amounts necessary for bone health. As 
reviewed, there is ample evidence that calcium and vitamin D 
alone have the ability to prevent bone loss and reduce frac-
ture. The one caveat is that compliance must be emphasized. 
Clearly, with diminished compliance the protective effects of 
calcium and vitamin D are lost. Continued discussions with 
patients to promote awareness of bone health and enhance 
compliance with calcium and vitamin D supplements, as well 
as prescription drugs, should be completed. Utilizing the entire 
health care team can be beneﬁ  cial in this quest. Ofﬁ  ce staff 
should understand and remind patients about bone health at 
key times, such as during scheduling of bone density testing. 
The health care provider should highlight proper nutrition 
and supplementation at pertinent times. For example, annual 
examinations are excellent times to review calcium and vitamin 
D intake with recommendations for supplementation reviewed. 
The pharmacist has a vital role in making patients aware of the 
need for calcium and vitamin D with prescription osteoporosis 
therapies, including proper administration to ensure absorption 
of bisphosphonate medications.
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